ALCHEMIA REPORTS NET LOSS OF $15.8M

ALCHEMIA REPORTS NET LOSS OF $15.8M

BRISBANE biotech company Alchemia (ASX:ACL) has reported a net loss of $15.8 million for the first half of the 2015 financial year, compared to $5.5 million for the six months ending 31 December 2013.

A contributing factor of this result was the failure of its recent cancer drug trial.

The pivotal phase three clinical trial of HA-Irinotecan in metastatic colorectal cancer failed to reach its primary endpoint in significant improvement in progression free survival and did not meet its secondary endpoint of an improvement in overall-survival.

This led to shares dropping by 83 per cent from 51.5 cents to 10.5 cents, in November 2014. 

Since the announcement of the above results, ACL has undergone a strategic review of all its assets and operations.

In addition, ACL has recorded profit share income arising from sales of fondaparinux - a collaboration agreement with Dr Reddy's Laboratories - of $2.8 million for the period and had net assets of $11.6 million.

In addition, operating expenditure of $24.9 million increased by $14.2 million over the corresponding period.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Employee resilience is key to business resilience
Partner Content
Employee mental health and wellbeing is top of mind for Australian businesses, and or...
Aon
Advertisement

Related Stories

Another week of masks for SEQ as authorities reveal backpacker case was turned away in WA

Another week of masks for SEQ as authorities reveal backpacker case was turned away in WA

With all eyes on the Sydney COVID-19 outbreak where another month...

Commonwealth raises COVID-19 Disaster Payment to JobKeeper levels

Commonwealth raises COVID-19 Disaster Payment to JobKeeper levels

The Federal Government's COVID-19 Disaster Payment will see e...

Dexus names Dap & Co for Naldham House fitout

Dexus names Dap & Co for Naldham House fitout

Dexus Property Group (ASX: DXS) hopes to restore Brisbane's&n...

Why governments will have to consider the costs of long COVID when easing pandemic restrictions

Why governments will have to consider the costs of long COVID when easing pandemic restrictions

With governments worldwide under pressure to ease pandemic restrict...